Endometrial Cancer Audit Pilot (ECAP)
Overview
There are over 9,700 new cases of uterine cancer diagnosed every year in the United Kingdom. Since the early 1990s, uterine cancer incidence rates have increased by around three-fifths (59%) in females in the UK. It is important that women diagnosed with uterine cancer receive the combination of treatments that will maximise survival, whilst minimising long term impacts on the patient.
The gynaecological oncology community is united in its commitment to establish high quality clinical audits of the management of gynaecological cancers which can drive improvements and reduce inequalities in care within the United Kingdom.
Following the highly successful and impactful Ovarian Cancer Audit Feasibility Pilot (OCAFP), which was a collaboration between the British Gynaecological Cancer Society (BGCS), Target Ovarian Cancer, Ovarian Cancer Action and the National Cancer Registration and Analysis Service (NCRAS), a national ovarian cancer audit was commissioned by Healthcare Quality Improvement Partnership (HQIP).
The BGCS proposes a similar project focussing on uterine cancer, with similar objectives to the OCAFP project to raise the profile of the disease, assess regional variation in management and outcome, and promote the call for a fully commissioned publicly funded national audit.
Collaboration
National Cancer Registration and Analysis Service (NCRAS), British Gynaecological Cancer Society (BGCS), British Association of Gynaecological Pathologists (BGAP), Peaches Womb Cancer Trust, Eve Appeal
Timeframe
2024-2026
Outcomes
The first report from the ECAP was published in April 2025. This baseline report provides a disease profile of endometrial cancer in England and presents findings on incidence, mortality and survival.
The second report from the ECAP was published in January 2026. This report outlines treatment patterns for endometrial cancer in England.
The third report from the ECAP was published in May 2026. This report provides a profile of routes to diagnosis, tumour genomic testing and immunotherapy use among women diagnosed with endometrial cancer in England.
HDI Team:Craig Knott | Melissa Gannon